STRO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107081 min ago

@ $4.45

Išleistas: 14 vas. 2024 @ 20:11

Grąža: -23.16%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -4.28 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	468 783
Vidutinė apimtis	994 533
Rinkos kapitalizacija	263.07M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.910 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.920
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.78
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

Tūris Koreliacija

Ilgas: -0.47 (neutral)

Trumpas: -0.20 (neutral)

Signal:(20.299) Neutral

Sutro Biopharma Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 Labiausiai neigiamai susiję koreliacijos
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sutro Biopharma Inc Koreliacija - Valiuta/Žaliavos

-0.73
( moderate negative )

-0.66
( moderate negative )

0.00
( neutral )

0.47
( neutral )

Sutro Biopharma Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$153.73M
Bruto pelnas:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2023
Pajamos:	$153.73M
Bruto pelnas:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2022
Pajamos:	$67.77M
Bruto pelnas:	$59.48M (87.77 %)
EPS:	$-2.35

FY	2021
Pajamos:	$61.88M
Bruto pelnas:	$61.88M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.